Search clinical trials for: Glargine Glulisine

Total 621 results

Sanofi

Completed

Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients (VARIABILITE)

Diabetes Mellitus, Type 1

France
Emory University

Completed

Glargine U300 Hospital Trial

Type 2 Diabetes

United States
Sanofi

Terminated

Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition

Diabetes Mellitus, Type 2

Brazil
Sanofi

Completed

Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study (GLANS)

Diabetes Mellitus, Type 1

Bahrain, Kuwait, Qatar, United Arab Emirates
Universidad Nacional de Asunción

Completed

Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay

Hyperglycemia | Diabetes

Paraguay
Sanofi

Completed

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Diabetes Mellitus

United States
Sanofi

Completed

Self Titration With Apidra to Reach Target Study (START)

Diabetes Mellitus, Type 2

Canada
Sanofi

Completed

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus (PORTAL 1)

Diabetes Mellitus, Type 1

Belarus
Sanofi

Completed

Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States
HaEmek Medical Center, Israel

Completed

Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards

Diabetes Mellitus Type 2
Sanofi

Completed

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day (SeLan)

Diabetes Mellitus, Type 2

Israel
Sanofi

Completed

Apidra Children & Adolescents Study

Diabetes Mellitus, Type 1

Russian Federation
Sanofi

Completed

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (GALAPAGOS)

Diabetes Mellitus, Type 2

Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)

Type 2 Diabetes Mellitus

India
Sanofi

Completed

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)

Diabetes Mellitus, Type 1

Tunisia, South Africa, Algeria, Argentina, Brazil, Colombia, Kuwait, Mexico, Saudi Arabia
Emory University
Sanofi

Completed

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis

United States
Sanofi

Terminated

Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients (LanScape)

Diabetes Mellitus, Type 2

Australia, United Kingdom
Emory University

Completed

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients (CABG-D/C)

Poor Glycemic Control

United States
Sanofi

Completed

Insulin Glulisine in Diabetes Mellitus, Type 2 (GINGER)

Diabetes Mellitus, Type 2

France, Spain, Italy, Belgium, Germany, Poland, Portugal, Czech Republic, Slovakia, Australia, Netherlands, Sweden, United Kingdom, Switzerland, Romania
Sanofi

Completed

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

Diabetes Mellitus

China
Population Health Research Institute

Completed

REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) (RECREATE Pilot)

Hyperglycemia | Myocardial Infarction | Cardiovascular Diseases

Argentina, Canada, India
India Diabetes Research Foundation & Dr. A. Ramachandran...

Completed

A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients

Type2 Diabetes

India
Guillermo Umpierrez, MD
Medical University of South Carolina; Sanofi; Texas A&M University

Completed

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM) (Basal-Plus)

Hyperglycemia | Type 2 Diabetes

United States
Sanofi

Completed

ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2

Italy
Sanofi

Terminated

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction (INTENSIVE)

AMI

Canada, Brazil, United States, Argentina, Mexico
Sanofi

Completed

Insulin Glargine "All to Target" Trial

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Opposing Step-by-step Insulin Reinforcement to Intensified Strategy (OSIRIS)

Diabetes Mellitus, Type 2

France, Korea, Republic of, Russian Federation, Spain, Italy, Belgium, Germany, Hungary, Ireland, Mexico, Poland, Taiwan, Turkey, Netherlands, Greece, Lithuania, Sweden, United Kingdom
Sanofi

Completed

Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. (DINAMO)

Diabetes Mellitus, Type 2

Brazil
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Sanofi

Completed

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (B to B)

Diabetes Mellitus, Type 2

Korea, Republic of
Emory University
Sanofi

Completed

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (RABBIT 2-SX)

Type 2 Diabetes | Inpatient Hyperglycemia

United States
Sanofi

Completed

Insulin Glulisine in Type 2 Diabetic Patients (Basal Plus)

Diabetes Mellitus, Type 2

Russian Federation, United States, United Kingdom
Cairo University

Completed

Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM

Diabetes Mellitus (DM)

Egypt
Guillermo Umpierrez

Completed

Diabetes in the Elderly: Prospective Study (DMElderly)

Hyperglycemia | Diabetes

United States
Sanofi

Completed

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (GetGoal-Duo-2)

Type 2 Diabetes

United States, Canada, Chile, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Cairo University
Sanofi

Unknown

Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial (VIRDICT)

Liver Cirrhosis | Type 2 Diabetes

Egypt
Sanofi

Completed

Insulin Glulisine in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Sanofi

Completed

Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus (SCALE)

Diabetes Mellitus

Egypt
Sanofi

Completed

APIDRA Registration Study

Diabetes Mellitus, Type 1

Kazakhstan
Sanofi

Completed

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Diabetes Mellitus, Insulin-Dependent

United States
Sanofi

Completed

Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Sanofi

Completed

Insulin Glulisine in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Rabin Medical Center
Sanofi

Terminated

Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents

Diabetes Type 1

Israel
Carl T. Hayden VA Medical Center
Sanofi

Completed

Comparison of Apidra to Regular Insulin in Hospitalized Patients (Apidra)

Diabetes Mellitus, Type II

United States
Sanofi

Completed

Insulin Glulisine in Healthy Lean and Obese Subjects

Diabetes Mellitus
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States

3

Subscribe